Get the Stockscreener App
129.93
2.07%
2.64
Pre-market:
129.71
-0.22
-0.17%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $129.93, with a volume of 5.67M.
It is up +2.07% in the last 24 hours and down -3.35% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$127.29
Open:
$127.45
24h Volume:
5.67M
Relative Volume:
0.85
Market Cap:
$226.06B
Revenue:
$43.11B
Net Income/Loss:
$13.98B
P/E Ratio:
16.28
EPS:
7.98
Net Cash Flow:
$6.78B
1W Performance:
+2.83%
1M Performance:
-3.35%
6M Performance:
+0.64%
1Y Performance:
+16.73%
1-Day Range:
$127.45
$130.13
1-Week Range:
$125.47
$130.13
52-Week Range:
$107.11
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
129.93 | 221.54B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.79 | 156.19B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
381.49 | 144.43B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
89.64 | 114.47B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.09 | 46.53B | 5.69B | 4.15B | 623.10M | 6.95 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Is it the right time to buy Abbott Laboratories stockTremendous wealth creation - jammulinksnews.com
How does Abbott Laboratories compare to its industry peersMaximize portfolio growth with professional advice - Jammu Links News
When is Abbott Laboratories stock expected to show significant growthConsistent high-performance stocks - jammulinksnews.com
RECKITT (RBGLY) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Reckitt Benckiser Group plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations - simplywall.st
Stock Analysis | Abbott Laboratories OutlookMixed Signals Amid Strong Fundamentals and Technical Uncertainty - AInvest
Similac NEC Lawsuit: 2025 Updates & List of Affected Formulas - Drugwatch.com
Abbott Laboratories Shares Drop 1.84 as Analysts Clash on Value Amid $850M Volume 155th in Market Activity - AInvest
How volatile is Abbott Laboratories stock compared to the marketMarket Forecast Signals For Fast Growth - Jammu Links News
Why Abbott Laboratories (ABT) Remains a Buy Despite Diagnostic Segment Weakness - AInvest
UBS Shrugs Abbott Laboratories’ (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating - MSN
Biotechnology Market is evolving rapidly Through 2025 To 2032 | Abbott Laboratories, Amgen Inc., GlaxoSmithKline - openPR.com
Abbott Gains 1.31% Amid 140th Trading Volume Rank as Analysts Weigh Diagnostic Sector Growth and Competitive Risks - AInvest
Meal Replacement Market Is Booming Worldwide 2025-2032 | Abbott - openPR.com
Paul MacDonald's Top Picks: Stryker, Abbott Labs & Elevance Health - BNN Bloomberg
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche - Yahoo Finance
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT) - MSN
2nd Abbott Baby Formula Bellwether Falls Before Trial - Law360
What institutional investors are buying Abbott Laboratories stockMaximize your portfolio’s growth potential - jammulinksnews.com
Does Abbott Laboratories stock perform well during market downturnsBuild a winning investment strategy today - jammulinksnews.com
RBC Capital gives Abbott Laboratories a thumbs-up, sees stock go higher. What's the best time to buy - AInvest
Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating - Insider Monkey
Abbott Laboratories' Q2 Earnings Report Presents Mixed Picture, Leerink Partners Decreases PT to $136, Maintains Hold Rating - AInvest
RBC Capital Bullish on Abbott Laboratories, Raises Price Target to $147. - AInvest
How does Abbott Laboratories generate profit in a changing economyMaximize your returns with portfolio optimization - jammulinksnews.com
Why is Abbott Laboratories stock attracting strong analyst attentionBuild wealth with steady, reliable stocks - jammulinksnews.com
Declining Stock and Solid Fundamentals: Is The Market Wrong About Abbott Laboratories (NYSE:ABT)? - Yahoo Finance
Continental Express wins fifth Abbott award - Sidney Daily News
Did Strong Q2 Results and Raised Guidance Just Shift Abbott Laboratories' (ABT) Investment Narrative? - simplywall.st
Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity - MSN
What analysts say about Abbott Laboratories stockConsistent high-performance stocks - PrintWeekIndia
Abbott Laboratories Stock Analysis and ForecastDynamic growth stocks - Autocar Professional
What drives Abbott Laboratories stock priceOutstanding capital appreciation - Autocar Professional
Abbott Laboratories (ABT): A Bull Case Theory - MSN
The Zacks Analyst Blog Highlights Wells Fargo, Abbott Laboratories, American Express, TSS and Maui Land & Pineapple - Yahoo Finance
Abbott Laboratories (ABT): I Am Very Upset With Abbott,” Says Jim Cramer - MSN
Top Stock Reports for Wells Fargo, Abbott & American Express - Yahoo Finance
Brianne Gardner's Top Picks: Abbott Labs, Chipotle Mexican Grill & Motorola Solutions - BNN Bloomberg
Jim Cramer Says He “Was Discouraged to Get a Mixed Update from Abbott Labs” - MSN
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Institutional owners may ignore Abbott Laboratories' (NYSE:ABT) recent US$10b market cap decline as longer-term profits stay in the green - Yahoo Finance
Notable healthcare headlines for the week: Trump’s tariff threats, J&J, Abbott Laboratories and Sarepta in focus - MSN
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):